Stock · MDT · Healthcare
Ireland · Large Cap · listed since 1978 · Revenue 12 mo. $37.5B
Price as of 11/06/2026
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally.
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring sys
Original text from the data provider
Summary
56.7 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €4.9B (2026), it supports €54.1B. The remaining €59.5B of the market value assume it grows 10.4% a year for 10 years and not at all afterwards.
Required FCF growth per year
10.4%
no growth afterwards
Price to operating cash flow 16.3×, within its usual range.
Middle half of 20 quarters: 15.4× to 18.2×, median 16.7×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
Since the last quarter
Q2 → Q3 2026
5 more unchanged: Revenue, 12 mo., EBIT margin, Net debt, Shares outstanding, Return on equity
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 9.70% | 11.52% | Rank 40 |
| Return on capital (Greenblatt) | 31.48% | 32.55% | Rank 48 |
| EBIT margin | 17.78% | 18.31% | Rank 48 |
| FCF margin | 14.92% | 14.12% | Rank 55 |
| Gross margin | 65.02% | 60.99% | Rank 56 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 8.43% | 8.04% | Rank 51 |
| Earnings growth, 3 years per year | 9.74% | 5.44% | Rank 59 |
| Earnings growth, 5 years per year | 6.95% | 7.00% | Rank 50 |
| Sustainable growth (ROE × retained earnings) | 5.24% | 3.66% | Rank 65 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 3.66% | 2.90% | Rank 64 |
| FCF yield | 4.29% | 3.63% | Rank 57 |
| EV/saleslower is better | 4.00 | 4.03 | Rank 50 |
| EV/EBITlower is better | 22.48 | 21.73 | Rank 48 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | 3.43% | 8.66% | Rank 46 |
| Share price, 6 months | 34.17% | 24.27% | Rank 74 |
| Share price, 3 months | 21.93% | 15.42% | Rank 72 |
| Distance from 52-week high | −3.37% | −7.35% | Rank 68 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | 0.44% | 0.30% | Rank 48 |
| Change in share countlower is better | −0.14% | 0.00% | Rank 54 |
| Dividend streak in years | 12 | 10 | Rank 65 |
| Price reaction to results, market-adjusted | 2.39% | 0.05% | Rank 67 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 53.17% | 48.40% | Rank 60 |
| Net debt/EBITDAlower is better | 1.91 | 1.11 | Rank 32 |
| Debt to equitylower is better | 0.57 | 0.48 | Rank 46 |
| Volatility, 1 yearlower is better | 24.88% | 31.42% | Rank 89 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF, $B | Shares | Net debt, $B |
|---|---|---|---|---|---|
| 2017 | 29.7 | 18.1% | 5.6 | 1.39B | 28.4 |
| 2018 | 30.0 | 22.2% | 3.6 | 1.37B | 22.1 |
| 2019 | 30.6 | 20.5% | 5.9 | 1.36B | 20.9 |
| 2020 | 28.9 | 16.6% | 6.0 | 1.35B | 20.7 |
| 2021 | 30.1 | 14.9% | 4.9 | 1.35B | 22.8 |
| 2022 | 31.7 | 18.2% | 6.0 | 1.35B | 20.4 |
| 2023 | 31.2 | 17.6% | 4.6 | 1.33B | 22.8 |
| 2024 | 32.4 | 15.9% | 5.2 | 1.33B | 23.7 |
| 2025 | 33.5 | 17.8% | 5.2 | 1.29B | 26.3 |
| 2026 | 36.4 | 17.8% | 5.4 | 1.29B | 26.0 |
2 of 7 StockScorer Score rules met · How the score is built
Medtronic PLC mainly meets criteria in the Valuation category. Result from 18 strategies checked.
Medtronic PLC is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
2 of 7 rules met
4 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Medtronic PLC.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 27.3 | 30.0 |
| P/B ratio | 2.7 | 4.8 |
| Return on equity (ROE) | 9.7% | 11.5% |
| Equity ratio | 53.2% | 48.4% |
| Debt-to-equity (D/E) | 0.57 | 0.48 |
| Dividend yield | 2.8% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| MDT | Medtronic PLCthis page | |
| SYK | Stryker Corporation | Low4.5 |
| ABT | Abbott Laboratories | High6.4 |
| BSX | Boston Scientific Corp | High9.1 |
| EW | Edwards Lifesciences Corp | locked |
| SHL.DE | Siemens Healthineers AG | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.